SG11202107983TA - Adeno-associated virus delivery of cln6 polynucleotide - Google Patents

Adeno-associated virus delivery of cln6 polynucleotide

Info

Publication number
SG11202107983TA
SG11202107983TA SG11202107983TA SG11202107983TA SG11202107983TA SG 11202107983T A SG11202107983T A SG 11202107983TA SG 11202107983T A SG11202107983T A SG 11202107983TA SG 11202107983T A SG11202107983T A SG 11202107983TA SG 11202107983T A SG11202107983T A SG 11202107983TA
Authority
SG
Singapore
Prior art keywords
cln6
adeno
polynucleotide
associated virus
virus delivery
Prior art date
Application number
SG11202107983TA
Other languages
English (en)
Inventor
Kathrin Meyer
Brian K Kaspar
Original Assignee
Res Inst Nationwide Childrens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Res Inst Nationwide Childrens Hospital filed Critical Res Inst Nationwide Childrens Hospital
Publication of SG11202107983TA publication Critical patent/SG11202107983TA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/63Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86Viral vectors
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011Details
    • C12N2750/14011Parvoviridae
    • C12N2750/14111Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
SG11202107983TA 2019-02-04 2020-02-04 Adeno-associated virus delivery of cln6 polynucleotide SG11202107983TA (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201962800915P 2019-02-04 2019-02-04
US201962880641P 2019-07-30 2019-07-30
US201962881151P 2019-07-31 2019-07-31
US201962912977P 2019-10-09 2019-10-09
US201962923125P 2019-10-18 2019-10-18
PCT/US2020/016541 WO2020163299A1 (en) 2019-02-04 2020-02-04 Adeno-associated virus delivery of cln6 polynucleotide

Publications (1)

Publication Number Publication Date
SG11202107983TA true SG11202107983TA (en) 2021-08-30

Family

ID=69771088

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202107983TA SG11202107983TA (en) 2019-02-04 2020-02-04 Adeno-associated virus delivery of cln6 polynucleotide

Country Status (14)

Country Link
US (1) US20220202956A1 (https=)
EP (1) EP3921429A1 (https=)
JP (2) JP2022519597A (https=)
KR (1) KR20210124299A (https=)
CN (2) CN113574176B (https=)
AU (1) AU2020218501B2 (https=)
BR (1) BR112021015150A2 (https=)
CA (1) CA3127801A1 (https=)
CL (1) CL2021002051A1 (https=)
IL (1) IL285329A (https=)
MX (1) MX2021009404A (https=)
SG (1) SG11202107983TA (https=)
TW (1) TW202033768A (https=)
WO (1) WO2020163299A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013296425B2 (en) 2012-08-01 2018-06-07 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
CA3137080A1 (en) * 2019-04-15 2020-10-22 Sanford Research Gene therapy for treating or preventing visual effects in batten disease
WO2023018674A1 (en) * 2021-08-09 2023-02-16 Amicus Therapeutics, Inc. Determination of gene transduction potency in neuron-like cells
WO2026039311A1 (en) 2024-08-10 2026-02-19 Vectorgen Lentiviral vector for treating human immunodeficiency virus infection

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU613316B2 (en) * 1986-09-12 1991-08-01 Genentech Inc. Improved recombinant expression
US5173414A (en) 1990-10-30 1992-12-22 Applied Immune Sciences, Inc. Production of recombinant adeno-associated virus vectors
WO1995013365A1 (en) 1993-11-09 1995-05-18 Targeted Genetics Corporation Generation of high titers of recombinant aav vectors
PT728214E (pt) 1993-11-09 2004-11-30 Ohio Med College Linhas celulares estaveis capazes de expressar o gene de replicacao do virus adeno-associado
US5658785A (en) 1994-06-06 1997-08-19 Children's Hospital, Inc. Adeno-associated virus materials and methods
SE9403613D0 (sv) * 1994-10-21 1994-10-21 Pharmacia Ab Improvement of an expression vector for production of recombinant proteins
US5856152A (en) 1994-10-28 1999-01-05 The Trustees Of The University Of Pennsylvania Hybrid adenovirus-AAV vector and methods of use therefor
CA2207927A1 (en) 1994-12-06 1996-06-13 Targeted Genetics Corporation Packaging cell lines for generation of high titers of recombinant aav vectors
FR2737730B1 (fr) 1995-08-10 1997-09-05 Pasteur Merieux Serums Vacc Procede de purification de virus par chromatographie
WO1997008298A1 (en) 1995-08-30 1997-03-06 Genzyme Corporation Chromatographic purification of adenovirus and aav
US6632670B1 (en) 1995-09-08 2003-10-14 Genzyme Corporation AAV vectors for gene therapy
US5910434A (en) 1995-12-15 1999-06-08 Systemix, Inc. Method for obtaining retroviral packaging cell lines producing high transducing efficiency retroviral supernatant
JP2001500497A (ja) 1996-09-06 2001-01-16 トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組換えアデノ随伴ウイルスに指図される遺伝子治療の方法
DK1009808T3 (da) 1997-09-05 2013-01-21 Genzyme Corp Fremgangsmåder til generering af hjælper-frie præparater af rekombinante aav-vektorer med høj titer
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6258595B1 (en) 1999-03-18 2001-07-10 The Trustees Of The University Of Pennsylvania Compositions and methods for helper-free production of recombinant adeno-associated viruses
US7056502B2 (en) 2000-04-28 2006-06-06 The Trustees Of The University Of Pennsylvania Recombinant aav vectors with AAV5 capsids and AAV5 vectors pseudotyped in heterologous capsids
JP3765574B2 (ja) * 2001-02-22 2006-04-12 三菱化学株式会社 逆向き反復配列を含む組み換え遺伝子及びその利用
US9233131B2 (en) 2003-06-30 2016-01-12 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9441244B2 (en) 2003-06-30 2016-09-13 The Regents Of The University Of California Mutant adeno-associated virus virions and methods of use thereof
US9434928B2 (en) 2011-11-23 2016-09-06 Nationwide Children's Hospital, Inc. Recombinant adeno-associated virus delivery of alpha-sarcoglycan polynucleotides
DE102012007232B4 (de) 2012-04-07 2014-03-13 Susanne Weller Verfahren zur Herstellung von rotierenden elektrischen Maschinen
AU2013296425B2 (en) * 2012-08-01 2018-06-07 Nationwide Children's Hospital Intrathecal delivery of recombinant adeno-associated virus 9
US9943611B2 (en) * 2012-11-01 2018-04-17 California Institute Of Technology Reversible gene expression
JP2015092462A (ja) 2013-09-30 2015-05-14 Tdk株式会社 正極及びそれを用いたリチウムイオン二次電池
WO2015141521A1 (ja) 2014-03-21 2015-09-24 株式会社日立国際電気 基板処理装置、半導体装置の製造方法及び記録媒体
JP6197169B2 (ja) 2014-09-29 2017-09-20 東芝メモリ株式会社 半導体装置の製造方法
WO2016100575A1 (en) * 2014-12-16 2016-06-23 Board Of Regents Of The University Of Nebraska Gene therapy for juvenile batten disease
CA3011939A1 (en) * 2016-02-02 2017-08-10 University Of Massachusetts Method to enhance the efficiency of systemic aav gene delivery to the central nervous system
EP3411484B1 (en) * 2016-02-05 2023-10-04 Emory University Injection of single-stranded or self-complementary adeno-associated virus 9 into the cerebrospinal fluid

Also Published As

Publication number Publication date
CA3127801A1 (en) 2020-08-13
IL285329A (en) 2021-09-30
TW202033768A (zh) 2020-09-16
EP3921429A1 (en) 2021-12-15
US20220202956A1 (en) 2022-06-30
AU2020218501A1 (en) 2021-08-19
AU2020218501B2 (en) 2026-01-29
CL2021002051A1 (es) 2022-04-08
CN113574176B (zh) 2025-06-06
JP2022519597A (ja) 2022-03-24
MX2021009404A (es) 2021-11-12
JP2025093922A (ja) 2025-06-24
BR112021015150A2 (pt) 2021-09-28
CN113574176A (zh) 2021-10-29
CN120505372A (zh) 2025-08-19
WO2020163299A1 (en) 2020-08-13
KR20210124299A (ko) 2021-10-14

Similar Documents

Publication Publication Date Title
SG11202103102WA (en) Adeno-associated virus compositions for targeted gene therapy
IL274712A (en) Adeno-associated virus variant capsids and use to prevent angiogenesis
IL279442A (en) Pharmaceutical preparations that include meloxicam
ZA202001679B (en) Adeno-associated virus variant capsids and methods of use thereof
SG11202107983TA (en) Adeno-associated virus delivery of cln6 polynucleotide
ZA201806863B (en) Adeno-associated virus vector delivery of b-sarcoglycan and microrna-29 and the treatment of muscular dystrophy
PT3565550T (pt) Composições farmacêuticas compreendendo meloxicam e rizatriptano
IL262353A (en) Methods for increasing the potency of a baculovirus system produced using a recombinant adeno-associated virus
DK3596222T5 (da) Adenoassocieret virusvektorfremføring af muskelspecifik mikro-dystrophin til behandling af muskeldystrofi
HUE071243T2 (hu) Mikro-disztrofin bejuttatása adeno-asszociált vírus vektorral izomdisztrófia kezelésére
PL3621621T3 (pl) Kompozycje farmaceutyczne zawierające meloksykam
IL255939B (en) Adeno-associated virus vectors for the treatment of mycopolysaccharidosis
EP3277819A4 (en) Adeno-associated virus variants and methods of use thereof
SG10202012832VA (en) Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
IL285328A (en) Delivery of cln3 polynucleotide by adeno-associated virus
IL283627A (en) Improved transport of large materials
IL285639A (en) Adeno-associated virus vectors for drug delivery
ZA202006541B (en) Pharmaceutical composition comprising brexpiprazole
IL277792A (en) Pharmaceutical compositions with reduced tert-butanol levels
GB201518456D0 (en) Novel compounds and pharmaceutical compositions thereof for the treatment of inflammatory, autoimmune and/or proliferative diseases
GB201713899D0 (en) Multi-dose medicament delivery device
IL285389A (en) Preparations containing meloxicam
GB201801896D0 (en) Medicament delivery devices
EP3302540A4 (en) Adeno-associated virus mediated delivery of c1ei as a therapy for angioedema
HK40055620A (en) Adeno-associated virus delivery of cln6 polynucleotide